Phase 1 open-label crossover RCT in 43 adults with seasonal allergic rhinitis: repeat-dose epinephrine nasal spray (neffy) gave higher or comparable peak levels and faster absorption vs IM epinephrine, including after nasal allergen challenge. All adverse events mild.
RCTn = 43
Oppenheimer et al. Pharmacokinetics and Pharmacodynamics Following Repeat Dosing of neffy (Epinephrine Nasal Spray) Versus Intramuscular Injection During Induced Allergic Rhinitis